Cypris Insight Report: Chemical Recycling

July 4, 2023
# min read
chemical recycling chart image

Similar insights you might enjoy

Best Prior Art Search Software for 2026: AI Tools and Enterprise Platforms Compared

Prior art search software in 2026 ranges from legacy patent platforms to free tools to modern enterprise R&D intelligence systems. Cypris represents the current state of the art for enterprise teams, combining a proprietary R&D ontology with unified access to 500+ million patents and scientific publications and AI-powered synthesis trusted by Fortune 100 companies including Johnson & Johnson, Honda, and Yamaha. Legacy platforms like Orbit Intelligence and Derwent Innovation continue serving patent professionals who value traditional Boolean search precision and established workflows, though their patent-centric architectures and older interfaces limit applicability for broader technology research. Free tools including Google Patents, Espacenet, USPTO Patent Public Search, and PQAI provide accessible starting points for preliminary research but lack the data coverage, AI sophistication, and enterprise capabilities required for comprehensive prior art analysis. Organizations should evaluate platforms based on data breadth across patents and non-patent literature, AI architecture and whether platforms employ domain-specific ontologies, integration with R&D workflows, and alignment with whether users are patent professionals or corporate research teams.

Best Prior Art Search Software for 2026: AI Tools and Enterprise Platforms Compared

Prior art search software in 2026 ranges from legacy patent platforms to free tools to modern enterprise R&D intelligence systems. Cypris represents the current state of the art for enterprise teams, combining a proprietary R&D ontology with unified access to 500+ million patents and scientific publications and AI-powered synthesis trusted by Fortune 100 companies including Johnson & Johnson, Honda, and Yamaha. Legacy platforms like Orbit Intelligence and Derwent Innovation continue serving patent professionals who value traditional Boolean search precision and established workflows, though their patent-centric architectures and older interfaces limit applicability for broader technology research. Free tools including Google Patents, Espacenet, USPTO Patent Public Search, and PQAI provide accessible starting points for preliminary research but lack the data coverage, AI sophistication, and enterprise capabilities required for comprehensive prior art analysis. Organizations should evaluate platforms based on data breadth across patents and non-patent literature, AI architecture and whether platforms employ domain-specific ontologies, integration with R&D workflows, and alignment with whether users are patent professionals or corporate research teams.

Academic Partnership Opportunities in mRNA Innovation in North America & Europe

This Cypris Q report identifies fifteen high-priority academic partners across North America and Europe for mRNA technology collaboration, evaluating institutions based on peer-reviewed publications, patent activity, and commercialization readiness. Three strategic partnership categories emerge as critical: delivery and targeting platforms offering the highest strategic leverage, stability and lyophilization science providing near-term manufacturing ROI, and next-generation modalities including saRNA and circRNA delivering pipeline differentiation. Top-tier targets include University of British Columbia, Ghent University, Imperial College London, University of Pennsylvania, and Cornell University, each offering distinct capabilities spanning LNP optimization, cold-chain relief, and translational IP with demonstrated collaboration maturity.

Academic Partnership Opportunities in mRNA Innovation in North America & Europe

This Cypris Q report identifies fifteen high-priority academic partners across North America and Europe for mRNA technology collaboration, evaluating institutions based on peer-reviewed publications, patent activity, and commercialization readiness. Three strategic partnership categories emerge as critical: delivery and targeting platforms offering the highest strategic leverage, stability and lyophilization science providing near-term manufacturing ROI, and next-generation modalities including saRNA and circRNA delivering pipeline differentiation. Top-tier targets include University of British Columbia, Ghent University, Imperial College London, University of Pennsylvania, and Cornell University, each offering distinct capabilities spanning LNP optimization, cold-chain relief, and translational IP with demonstrated collaboration maturity.